JP2023506452A5 - - Google Patents
Info
- Publication number
- JP2023506452A5 JP2023506452A5 JP2022535518A JP2022535518A JP2023506452A5 JP 2023506452 A5 JP2023506452 A5 JP 2023506452A5 JP 2022535518 A JP2022535518 A JP 2022535518A JP 2022535518 A JP2022535518 A JP 2022535518A JP 2023506452 A5 JP2023506452 A5 JP 2023506452A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antibody
- seq
- fusion protein
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947686P | 2019-12-13 | 2019-12-13 | |
| US62/947,686 | 2019-12-13 | ||
| PCT/US2020/064515 WO2021119429A1 (en) | 2019-12-13 | 2020-12-11 | Novel interleukin-15 (il-15) fusion proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506452A JP2023506452A (ja) | 2023-02-16 |
| JP2023506452A5 true JP2023506452A5 (cg-RX-API-DMAC7.html) | 2023-12-19 |
| JP7807076B2 JP7807076B2 (ja) | 2026-01-27 |
Family
ID=76330576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535518A Active JP7807076B2 (ja) | 2019-12-13 | 2020-12-11 | 新規インターロイキン-15(il-15)融合タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230048046A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4461750A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7807076B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220114063A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115087464B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020402097A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3164337A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119429A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| WO2019204646A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2022012428A1 (zh) * | 2020-07-14 | 2022-01-20 | 迈威(上海)生物科技股份有限公司 | 抗pd-1抗体及其稳定制剂 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| WO2023280307A1 (en) * | 2021-07-09 | 2023-01-12 | Nanjing Legend Biotech Co., Ltd. | Mutant il-15 compositions and methods thereof |
| KR20230044131A (ko) * | 2021-09-24 | 2023-04-03 | 바이오엔시스템스 주식회사 | Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도 |
| WO2023060156A2 (en) * | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2023133424A2 (en) * | 2022-01-05 | 2023-07-13 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides |
| WO2023160721A1 (en) * | 2022-02-28 | 2023-08-31 | Wuxi Biologics (Shanghai) Co., Ltd. | Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof |
| US20240025968A1 (en) * | 2022-04-07 | 2024-01-25 | Xencor, Inc. | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS |
| CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
| WO2024054425A1 (en) * | 2022-09-08 | 2024-03-14 | Cugene Inc. | Novel pd1-targeted il-15 immunocytokine and vitokine fusions |
| CN116063512B (zh) * | 2022-10-13 | 2025-11-07 | 深圳市百士通科技开发有限公司 | 多功能重组抗体及其制备方法和应用 |
| KR20250135294A (ko) * | 2023-02-21 | 2025-09-12 | 레메젠 코, 리미티드 | 암을 위한 il-15 작용제 |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025252855A1 (en) * | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta |
| CN118995825B (zh) * | 2024-10-24 | 2025-02-07 | 星奕昂(上海)生物科技有限公司 | 一种特异性定量标定白细胞介素15活性的细胞系及其应用 |
| CN121362261A (zh) * | 2025-10-30 | 2026-01-20 | 北京再青生物科技有限公司 | 一种靶向T细胞及Her2的双特异性抗体并串联IL-15及其受体的融合蛋白及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| KR20050049545A (ko) * | 2002-10-14 | 2005-05-25 | 에프. 호프만-라 로슈 아게 | 길항제 il-15 |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009298131B2 (en) * | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| CA2769473A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| EP3093295B1 (en) * | 2014-01-08 | 2020-05-27 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-15 heterogeneous dimer protein and uses thereof |
| US10858452B2 (en) * | 2015-09-16 | 2020-12-08 | Insitut National de la Sante et de la Recherche Medicale (INSERM) | Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| US10975155B2 (en) * | 2016-05-13 | 2021-04-13 | Medimmune, Llc | CD40L-Fc fusion polypeptides and methods of use thereof |
| MX2019004327A (es) * | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| AU2018291497A1 (en) * | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| JP7386161B2 (ja) * | 2017-12-19 | 2023-11-24 | ブレイズ バイオサイエンス, インコーポレイテッド | 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法 |
| AU2019224159B2 (en) * | 2018-02-26 | 2025-05-29 | Sanofi | IL-15 conjugates and uses thereof |
| CA3090407A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| CA3097625A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| CN121086085A (zh) * | 2018-06-22 | 2025-12-09 | 科优基因公司 | 新型白介素-15 (il-15)融合蛋白及其用途 |
| CA3116188A1 (en) * | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| AU2020403148A1 (en) * | 2019-12-13 | 2022-06-30 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
-
2020
- 2020-12-11 KR KR1020227024241A patent/KR20220114063A/ko active Pending
- 2020-12-11 EP EP24191000.9A patent/EP4461750A3/en active Pending
- 2020-12-11 WO PCT/US2020/064515 patent/WO2021119429A1/en not_active Ceased
- 2020-12-11 CN CN202080096546.5A patent/CN115087464B/zh active Active
- 2020-12-11 AU AU2020402097A patent/AU2020402097A1/en active Pending
- 2020-12-11 EP EP20899197.6A patent/EP4072588A4/en not_active Withdrawn
- 2020-12-11 JP JP2022535518A patent/JP7807076B2/ja active Active
- 2020-12-11 US US17/784,186 patent/US20230048046A1/en active Pending
- 2020-12-11 CA CA3164337A patent/CA3164337A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536345A5 (cg-RX-API-DMAC7.html) | ||
| JP6618463B2 (ja) | 三量体型抗原結合分子 | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2025065142A5 (cg-RX-API-DMAC7.html) | ||
| JP2022513116A5 (cg-RX-API-DMAC7.html) | ||
| JP2022105574A (ja) | 多重特異性分子 | |
| EP3253795B1 (en) | Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments | |
| JP2019524693A5 (cg-RX-API-DMAC7.html) | ||
| JP2022536347A5 (cg-RX-API-DMAC7.html) | ||
| JP2019528077A5 (cg-RX-API-DMAC7.html) | ||
| JP2021515806A (ja) | 三重特異性抗原結合タンパク質 | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| RU2017129591A (ru) | МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК | |
| JP2019531704A5 (cg-RX-API-DMAC7.html) | ||
| JP2024023228A5 (cg-RX-API-DMAC7.html) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2017521998A (ja) | 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法 | |
| RS56879B1 (sr) | Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2022009816A5 (cg-RX-API-DMAC7.html) | ||
| JP2024509910A5 (cg-RX-API-DMAC7.html) | ||
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JP2024527020A5 (cg-RX-API-DMAC7.html) | ||
| CN120548192A (zh) | 免疫缀合物 |